

## SUMMARY OF APPEAL/RECONSIDERATION REQUESTS

### Strategic Partnership 3 Applications

APP #	ACTION	SCORE	TIER		
SP3A-07536		76	1		
SP3A-07552		76	1		
SP3A-07526	Applicant consulted with Review Office and chose to submit a request for reconsideration based on material new information. The data submitted was allowable and addressed a major criticism of the GWG. Specifically, the data provided additional evidence that the therapeutic candidate targets cancer stem cells. As the new information may have affected the outcome of the GWG recommendation, the application will be deferred for further review by a GWG subcommittee.	74	2		
SP3A-07548	Applicant consulted with Review Office and chose to submit a request for reconsideration based on material new information. Request for reconsideration was denied as the information provided did not meet the criteria for material new information.	71	2		
SP3A-07559	Applicant consulted with Review Office and chose to submit a request for reconsideration based on material new information. Some of the data submitted was new and addressed a specific criticism of the GWG. Although the new data partly resolves this criticism, CIRM concluded that in light of other reviewer concerns, the recommendation by the GWG would not have affected the overall outcome.	68	2		
SP3A-07529		-	3		